<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study aimed to investigate the efficacy of <z:chebi fb="0" ids="51450">bosentan</z:chebi> in the treatment of severe <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> in a young female patient with <z:e sem="disease" ids="C0026272" disease_type="Disease or Syndrome" abbrv="MCTD">mixed connective tissue disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e>) associated with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A 27-year-old woman presented with sudden <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0002094'>dyspnea</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>She had not experienced any <z:hpo ids='HP_0002094'>dyspnea</z:hpo> before this period, and she was known to have <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Laboratory tests showed positive results for <z:hpo ids='HP_0003493'>antinuclear antibodies</z:hpo>, anti-RNP antibodies, anticardiolipin antibodies, beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I, and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>A complete echocardiographic study was performed demonstrating a pulmonary artery systolic pressure (<z:mp ids='MP_0010998'>PAPs</z:mp>) of 85 mmHg </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with <z:chebi fb="0" ids="51450">bosentan</z:chebi> was initiated </plain></SENT>
<SENT sid="6" pm="."><plain>After 12 days, the patient improved clinically </plain></SENT>
<SENT sid="7" pm="."><plain>After 6 months of therapy, the follow-up echocardiography showed a near-normalization of <z:mp ids='MP_0010998'>PAPs</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Patients who develop <z:chebi fb="11" ids="104011,31204,33848,53305">PAH</z:chebi> secondary to an underlying <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic disease</z:e> often have a poor survival rate </plain></SENT>
<SENT sid="9" pm="."><plain>In this report, we describe a correlation between anticardiolipin antibodies and <z:hpo ids='HP_0003678'>rapidly progressive</z:hpo> <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Indeed, the patient in this study very likely improved secondary to the effect of <z:chebi fb="0" ids="51450">bosentan</z:chebi> which produces systemic and pulmonary vasodilatation associated with pulmonary vascular remodeling as well as possible antifibrotic, anti-inflammatory and antiatherothrombotic effects on cells of lungs damaged by an aPL-antibody mediated mechanism </plain></SENT>
</text></document>